Skip to main content

Table 5 P. aeruginosa and Acinetobacter spp isolated from ICU patients during 2000–2002

From: Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American Surveillance study (2000–2002)

  

United States

Canada

Italy

Germany

France

Organism

Agent

Total n

%S

%R

Total n

%S

%R

Total n

%S

%R

Total n

%S

%R

Total n

%S

%R

Acinetobacter species

Cefepime

5,162

43.8

40.2

97

67.0

23.7

475

17.9

73.7

623

74.2

10.8

857

28.0

40.3

 

Cefotaxime

3,830

23.3

49.9

705

36.7

34.9

555

11.0

78.7

1,254

34.9

24.6

671

15.4

38.7

 

Ceftazidime

5,954

42.2

40.8

1,162

70.8

22.9

692

25.6

68.5

988

66.7

14.5

1,106

34.9

35.5

 

Ceftriaxone

4,709

16.3

55.9

874

32.4

28.7

452

8.8

72.6

104

42.3

11.5

81

9.9

51.9

 

Ciprofloxacin

5,808

39.7

58.0

1,156

72.1

25.9

686

21.1

76.7

1,126

74.8

22.9

1,038

37.7

61.2

 

Gentamicin

6,618

47.2

47.2

1,185

72.8

22.8

768

23.3

72.4

979

82.0

14.1

936

49.3

43.5

 

Imipenem

6,006

87.0

7.5

918

95.8

1.9

569

77.9

19.0

1,253

96.2

3.4

1,088

93.8

3.8

 

Levofloxacin

5,099

43.8

52.2

489

61.1

25.6

295

13.9

75.3

840

82.0

10.5

NTb

NT

NT

 

Meropenem

2,154

66.3

26.5

348

93.7

4.9

455

74.5

13.6

1,024

96.0

3.4

147

68.0

28.6

 

Piperacillin

4,658

35.4

45.9

959

66.5

19.5

635

19.5

69.9

1,171

59.7

12.9

805

35.0

50.3

 

Piperacillin-tazobactam

3,429

53.6

28.5

903

70.7

23.1

425

35.1

46.4

1,225

81.8

7.5

878

74.5

10.5

 

Trimethoprim-sulfamethoxazole

5,697

51.4

48.4

1,155

74.8

25.2

750

44.1

55.7

1,234

83.6

15.6

93

45.2

52.7

Pseudomonas aeruginosa

                
 

Cefepime

20,220

72.5

12.4

371

73.3

12.4

5,056

58.9

28.9

3,483

80.3

7.8

7,967

52.6

16.2

 

Cefotaxime

11,283

9.2

50.4

1,836

13.3

47.5

4,181

6.0

70.7

2,689

7.7

52.2

NT

NT

NT

 

Ceftazidime

26,353

71.2

17.4

6,036

73.7

13.4

7,640

56.7

31.3

5,141

76.2

14.9

8,547

70.2

14.9

 

Ceftriaxone

14,066

12.1

56.4

2,847

11.3

59.7

3,383

8.4

70.4

154

26.6

7.8

NT

NT

NT

 

Ciprofloxacin

26,700

62.8

33.1

5,924

67.2

30.2

7,388

58.4

38.8

4,746

68.6

24.4

8,560

55.3

40.6

 

Gentamicin

29,268

69.4

21.5

5,951

72.2

15.9

7,522

52.2

41.7

3,913

74.0

14.3

7,327

44.0

46.1

 

Imipenem

26,076

73.5

22.1

3,775

77.9

18.2

7,057

59.7

27.8

4,412

70.5

19.0

8,575

69.5

21.4

 

Levofloxacin

21,059

62.7

31.7

713

56.8

33.5

2,427

44.9

51.0

2,953

68.0

23.9

NT

NT

NT

 

Meropenem

7,540

76.0

18.2

1,266

80.3

14.5

4,082

57.3

32.7

4,351

77.8

13.8

1,818

81.1

6.4

 

Piperacillin

22,855

77.7

22.2

5,520

80.9

18.8

7,004

63.1

36.7

4,554

81.7

14.1

8,454

64.1

24.1

 

Piperacillin-tazobactam

21,848

85.5

14.4

4,190

91.0

9.0

5,252

77.7

22.0

4,746

85.8

10.7

8,256

69.6

15.9

Trimethoprim-sulfamethoxazole

15,618

3.6

96.4

4,283

4.0

96.0

7,054

4.1

95.8

3,375

4.2

95.8

NT

NT

NT

 
  1. aNCCLS breakpoints were used for all countries, except France (CA-SFM) bNT = not tested